X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs LUPIN LTD - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. LUPIN LTD FRESENIUS KABI ONCO./
LUPIN LTD
 
P/E (TTM) x 22.1 16.4 135.2% View Chart
P/BV x 3.1 3.8 81.6% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 FRESENIUS KABI ONCO.   LUPIN LTD
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
LUPIN LTD
Mar-16
FRESENIUS KABI ONCO./
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1762,127 8.3%   
Low Rs791,294 6.1%   
Sales per share (Unadj.) Rs37.7304.1 12.4%  
Earnings per share (Unadj.) Rs5.150.4 10.1%  
Cash flow per share (Unadj.) Rs6.760.7 11.1%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs42.5243.8 17.5%  
Shares outstanding (eoy) m158.23450.58 35.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.6 60.0%   
Avg P/E ratio x25.033.9 73.6%  
P/CF ratio (eoy) x18.928.2 67.1%  
Price / Book Value ratio x3.07.0 42.6%  
Dividend payout %014.9 0.0%   
Avg Mkt Cap Rs m20,135770,740 2.6%   
No. of employees `0001.216.4 7.0%   
Total wages/salary Rs m70321,077 3.3%   
Avg. sales/employee Rs Th5,176.28,379.6 61.8%   
Avg. wages/employee Rs Th610.41,289.0 47.4%   
Avg. net profit/employee Rs Th699.61,388.7 50.4%   
INCOME DATA
Net Sales Rs m5,963137,016 4.4%  
Other income Rs m181,877 1.0%   
Total revenues Rs m5,981138,893 4.3%   
Gross profit Rs m1,43037,535 3.8%  
Depreciation Rs m2584,635 5.6%   
Interest Rs m-26446 -5.8%   
Profit before tax Rs m1,21634,330 3.5%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m34211,536 3.0%   
Profit after tax Rs m80622,707 3.5%  
Gross profit margin %24.027.4 87.5%  
Effective tax rate %28.133.6 83.7%   
Net profit margin %13.516.6 81.6%  
BALANCE SHEET DATA
Current assets Rs m5,10297,790 5.2%   
Current liabilities Rs m2,38553,872 4.4%   
Net working cap to sales %45.632.1 142.1%  
Current ratio x2.11.8 117.8%  
Inventory Days Days15085 177.2%  
Debtors Days Days113121 93.5%  
Net fixed assets Rs m5,14886,379 6.0%   
Share capital Rs m158901 17.6%   
"Free" reserves Rs m6,556105,735 6.2%   
Net worth Rs m6,732109,844 6.1%   
Long term debt Rs m95253,739 1.8%   
Total assets Rs m10,388224,378 4.6%  
Interest coverage x-45.877.9 -58.7%   
Debt to equity ratio x0.10.5 28.9%  
Sales to assets ratio x0.60.6 94.0%   
Return on assets %7.510.3 72.8%  
Return on equity %12.020.7 57.9%  
Return on capital %14.621.2 68.9%  
Exports to sales %74.549.1 151.7%   
Imports to sales %24.87.4 332.8%   
Exports (fob) Rs m4,44167,244 6.6%   
Imports (cif) Rs m1,47710,199 14.5%   
Fx inflow Rs m5,29871,405 7.4%   
Fx outflow Rs m1,77217,807 10.0%   
Net fx Rs m3,52553,598 6.6%   
CASH FLOW
From Operations Rs m1,274-3,690 -34.5%  
From Investments Rs m-1,204-69,434 1.7%  
From Financial Activity Rs m-19658,126 -0.3%  
Net Cashflow Rs m-126-14,998 0.8%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 81.0 0.2 40,500.0%  
Indian inst/Mut Fund % 0.3 11.3 2.7%  
FIIs % 9.6 31.9 30.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.1 90.1%  
Shareholders   42,599 98,259 43.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   PLETHICO PHARMA  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Infosys Down 4.1%(09:30 am)

Asian stock markets opened mixed in early trade today. Hong Kong Hang Seng has advanced 143 points and China's Shanghai Composite has gained 9 points.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS